Conference Call Participants
Daniel Ferry – Lifesci Advisors, LLC
Yasmeen Rahimi – Piper Sandler & Co., Research Division
Ritu Baral – TD Cowen, Research Division
Tiago Fauth – Raymond James & Associates, Inc., Research Division
François Brisebois – LifeSci Capital, LLC, Research Division
Yatin Suneja – Guggenheim Securities, LLC, Research Division
Kambiz Yazdi – BTIG, LLC, Research Division
Lin Tsai – Jefferies LLC, Research Division
David Hoang – Deutsche Bank AG, Research Division
Jay Olson – Oppenheimer & Co. Inc., Research Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Research Division
Brian Skorney – Robert W. Baird & Co. Incorporated, Research Division
Presentation
Operator
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Praxis Precision Medicines First Quarter 2026 Financial Results Conference Call.
[Operator Instructions]
As a reminder, this conference call is being recorded. At this time, I would like to turn the conference over to Mr. Dan Ferry of LifeSci Advisors. Sir, please begin.
Daniel Ferry
Lifesci Advisors, LLC
Good morning, and welcome to Praxis Precision Medicines First Quarter 2026 Financial Results and Business Update Conference Call.
This call is being webcast live and can be accessed on the Investors section of Praxis’ website @www.praxismedicines.com. Please note that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These may include statements about the company’s future expectations and plans, clinical development timelines, and financial projections.
While these forward-looking statements represent Praxis’ views as of today, they should not be relied upon as representing the company’s views in the future.
Praxis may update these statements in the future, but is not taking on an
